Navigation Links
Gene signature spells poor outcome
Date:8/30/2007

Other than visually inspecting the disease, doctors have no genetic blueprint to classify melanomas, a lethal form of skin cancer. Tumors generally are ranked by how deeply the growth has invaded underlying skin tissue. The deeper it burrows into the skin, the more lethal the cancer, but some patients defy the odds and survive with thick tumors or die from thin ones. Two melanoma patients with cancers of the same invasion depth and appearance under the microscope can have completely different outcomes, says Rhoda Alani, M.D., associate professor of oncology, dermatology and molecular biology and genetics at Hopkins Kimmel Cancer Center.

Alani says the way genes turn their protein-manufacturing machinery on and off in each cancer may help create a signature that can be used to identify tumors that are more prone to kill. These so-called expression patterns can be different from one stage of cancer to the next.

Her research team charted the level of gene expression in melanoma cell lines. Three of the lines mimic the least aggressive type, which grows along the uppermost surface of the skin, called radial growth phase. Four of the cell lines are typical of so-called vertical growth phase cancers, which invade inner skin layers, and another three represent the most lethal form -metastatic melanomas.

Two vertical growth phase cell lines had gene expression patterns similar to radial growth cancers, indicating that these cells were less aggressive, according to the scientists. The remaining two vertical growth cell lines contained patterns in 18 genes that paralleled metastatic cancer cell lines, the most aggressive form. Alani and her colleagues believe that within this group of 18 genes is a signature for aggressive melanomas.

Many of the genes described in the Hopkins report, published online on July 4 in PLoS One, were previously identified as associated with aggressive cancers by scientists at Johns Hopkins and else
'/>"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Predicting Breast Cancer Recurrence By Understanding Gene Signature
2. Signature Campaign: Striking doctors take to the streets
3. Attention! Spells of momentary blindness following visual disturbance
4. Uncontrolled Diabetes Spells Doom for Dental Implants
5. Lip Service : Indiscriminate Kissing Spells Doom
6. Medicare Bulk Billing Spells Ill Health For The Health System
7. Community Health Shake-up Spells Trouble for Nurses
8. Heat Spells Trouble in South Carolina
9. The DNA That Spells Double Risk of Heart Attack
10. The DNA That Spells Double Risk of Heart Attack
11. Antifever drug betters stroke outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 25, 2014 Parker & ... outstanding customer service and affordable quality regarding heating, cooling ... announces recognition in 2014 by the “Queen of Clean” ... has earned an impressive reputation over the years for ... a wide range of contractor services for both homeowners ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of fields ... biology, and research for metabolic and genetic disorders. It ... used techniques for the discovery and development of cancer ... rapidly growing worldwide. In 2012, there were 14.1 million ... million people living with cancer (within five years of ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The ... that allege the blood thinner caused life-threatening episodes ... a leadership structure for the proceeding, Bernstein Liebhard ... 17th, the Court plans to select lawyers to ... also plans on appointing a Plaintiffs’ Steering Committee, ...
(Date:12/24/2014)... TX (PRWEB) December 25, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. Stivarga is a drug which is used ... drug is orally administered and is also prescribed to ... drug which is FDA approved is a multi-kinase inhibitor ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... is Leading Proponent for Single-Payer Healthcare ... Reforms - ,Medicare ... camera on the,fastest-growing union in America -- and the nation,s ... California Nurses,Association/National Nurses Organizing Committee,s fight for guaranteed,single-payer healthcare in ...
... odds of heart attack, death, study finds , , THURSDAY, May ... can hear when passing a stethoscope over a main artery ... attack and death from heart disease and stroke, a new ... (pronounced brew-ee) -- is caused by turbulent blood flow due ...
... 6, 2008) The American Society of Hematology (ASH) ... for its 2008 Minority Medical Student Award Program (MMSAP), ... in hematology research. Under the program, each award recipient ... a career development mentor, travel stipends to attend medical ...
... $0.18 In Line with Previously Announced ... Expectations, ... largest air medical transportation company in the,world, reported financial results for the ... flight volumes. For the quarter,revenue increased 45.0% to $118.1 million from $81.5 ...
... Corporation is launching a,third dental industry-focused online Tradeshow, ... is now open and available at, http://www.ddstechfair.com . ... bring dental professionals together with,colleagues and manufacturers at ... Tech Fair is designed to give the dental ...
... role in development of defective cells in type 2 diabetics ... an important gene during fetal development appears to increase vulnerability ... , Intrauterine growth retardation (IUGR), which causes low birth ... type 2 diabetes and other diseases when a child grows ...
Cached Medicine News:Health News:Bill Moyers' Journal to Feature California Nurses Association/National Nurses Organizing Committee in Friday, May 9th Episode 2Health News:Noise in Artery Could Warn of Heart Risk 2Health News:Minority medical students receive support to increase diversity in hematology 2Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 2Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 3Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 4Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 5Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 6Health News:PennWell Announces DDS Tech Fair 2Health News:Fetal Gene May Contribute to Diabetes Risk 2
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... - First of three ongoing randomized chemotherapy combination trials ... HGS-ETR1 in the treatment of specific cancers -, ... HGSI ) today reported initial topline results from,an ... receptor antibody,HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in ...
... This Common and Successful Surgery, ROCHESTER, Minn., ... issue of Mayo Clinic Health Letter. You may,cite ... is allowed for a,fee. Mayo Clinic Health Letter ... your editorial policies permit: Visit, http://www.HealthLetter.MayoClinic.com or ...
Cached Medicine Technology:Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 2Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 3Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 4Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 5Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 6September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 2September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 3September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: